Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
CTLA-4 inhibitor
PD-1 inhibitor
PD-L1 inhibitor
hazard ratio
immune checkpoint inhibitors
overall survival
progression-free survival
tumor mutational burden
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Nov 2019
15 Nov 2019
Historique:
received:
06
10
2019
revised:
10
11
2019
accepted:
12
11
2019
entrez:
17
11
2019
pubmed:
17
11
2019
medline:
17
11
2019
Statut:
epublish
Résumé
Tumor mutational burden (TMB) is a genomic biomarker that predicts favorable responses to immune checkpoint inhibitors (ICIs). Here, we set out to assess the predictive value of TMB on long-term survival outcomes in patients undergoing ICIs. We systematically searched PubMed, Embase, CENTRAL and clinicaltrials.gov from inception to 6 August 2019. We included retrospective studies or clinical trials of ICIs that reported hazard ratios (HRs) for overall survival (OS) and/or progression-free survival (PFS) according to TMB. Data on 5712 patients from 26 studies were included. Among patients who received ICIs, high TMB groups showed better OS (HR 0.53, 95% CI 0.42 to 0.67) and PFS (HR 0.52, 95% CI 0.40 to 0.67) compared to low TMB groups. In patients with high TMB, those who received ICIs had a better OS (HR 0.69, 95% CI 0.50 to 0.95) and PFS (HR = 0.66, 95% CI = 0.47 to 0.92) compared to those who received chemotherapy alone, while in patients with low TMB, such ICI benefits of OS or PFS were not statistically significant. In conclusion, TMB may be an effective biomarker to predict survival in patients undergoing ICI treatment. The role of TMB in identifying patient groups who may benefit from ICIs should be determined in future randomized controlled trials.
Identifiants
pubmed: 31731749
pii: cancers11111798
doi: 10.3390/cancers11111798
pmc: PMC6895916
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JCO Precis Oncol. 2017;2017:null
pubmed: 29951597
JAMA Oncol. 2019 Apr 1;5(4):529-536
pubmed: 30605213
Mol Diagn Ther. 2019 Aug;23(4):507-520
pubmed: 31250328
J Clin Oncol. 2017 Dec 10;35(35):3924-3933
pubmed: 29023213
Ann Oncol. 2019 Aug 1;30(8):1232-1243
pubmed: 31056702
Dis Colon Rectum. 2016 Dec;59(12):1174-1182
pubmed: 27824703
Oncologist. 2019 Jun;24(6):820-828
pubmed: 30867242
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Clin Cancer Res. 2019 Aug 15;25(16):5015-5026
pubmed: 31085721
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Lung Cancer. 2017 Oct;112:200-215
pubmed: 29191596
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Lancet Oncol. 2016 Dec;17(12):e542-e551
pubmed: 27924752
JAMA Oncol. 2016 Jan;2(1):15-6
pubmed: 26562503
JCI Insight. 2019 Mar 21;4(6):null
pubmed: 30895946
Clin Cancer Res. 2017 Oct 1;23(19):5729-5736
pubmed: 28972084
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
Lancet Oncol. 2018 Aug;19(8):e375
pubmed: 30102225
Genome Med. 2018 Nov 29;10(1):93
pubmed: 30497521
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Nat Genet. 2018 Sep;50(9):1271-1281
pubmed: 30150660
Clin Cancer Res. 2019 Oct 15;25(20):6061-6072
pubmed: 31358540
J Natl Cancer Inst. 2015 Aug 20;107(11):
pubmed: 26296643
Cancer Immunol Res. 2017 Jan;5(1):84-91
pubmed: 27956380
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
J Immunother Cancer. 2019 Nov 6;7(1):287
pubmed: 31694714
Clin Lung Cancer. 2019 Mar;20(2):88-96.e6
pubmed: 30425022
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
J Manag Care Spec Pharm. 2017 Jun;23(6):653-664
pubmed: 28530525
J Immunother Cancer. 2019 Mar 28;7(1):87
pubmed: 30922388
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Radiology. 2018 Jun;287(3):983-992
pubmed: 29533721
Int J Cancer. 2019 Feb 15;144(4):848-858
pubmed: 30238975
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
JAMA Netw Open. 2019 Jul 3;2(7):e196879
pubmed: 31290993
Cancer Immunol Res. 2016 Nov;4(11):959-967
pubmed: 27671167
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Oncoimmunology. 2019 Jun 16;8(9):e1629258
pubmed: 31428527
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
JAMA Oncol. 2017 Aug 1;3(8):1051-1058
pubmed: 28278348
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
Cancer Immunol Res. 2018 Oct;6(10):1260-1273
pubmed: 30012633
J Clin Oncol. 2017 Dec 1;35(34):3867-3876
pubmed: 29053400
Cancer Immunol Res. 2019 Mar;7(3):458-465
pubmed: 30635271
Lancet Oncol. 2018 Jun;19(6):737-746
pubmed: 29778737
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Cancer Cell. 2018 May 14;33(5):843-852.e4
pubmed: 29657128
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
BMC Med. 2016 Oct 25;14(1):168
pubmed: 27776519
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
J Manag Care Spec Pharm. 2017 Feb;23(2):184-194
pubmed: 28125365
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
Transl Lung Cancer Res. 2018 Dec;7(6):647-660
pubmed: 30505709
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Radiother Oncol. 2017 Aug;124(2):256-262
pubmed: 28764926
BMJ. 2018 Sep 10;362:k3529
pubmed: 30201790
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Lancet Oncol. 2018 Mar;19(3):310-322
pubmed: 29449192
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640
Ann Oncol. 2019 Sep 1;30(9):1479-1486
pubmed: 31236579
Ann Oncol. 2017 Oct 1;28(10):2377-2385
pubmed: 28945858
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120